Mian XI

Mianxi Biopharma is a China-based biotechnology company specializing in the discovery and development of next-generation targeted protein degradation (TPD) therapies, specifically molecular glues. Headquartered in Shanghai, the company utilizes its proprietary GlueXplorer platform to identify small molecules that induce the degradation of disease-causing proteins previously considered "undruggable." The platform integrates advanced structural biology, high-throughput screening, and computational modeling to accelerate the drug discovery process. Mianxi's primary therapeutic focus is on oncology and immunology, where it aims to develop highly selective degraders with improved pharmacological properties. The company is backed by prominent venture capital firms, including Qiming Venture Partners, reflecting its potential in the rapidly evolving TPD landscape. By expanding the library of recruitable E3 ligases and target proteins, Mianxi seeks to provide transformative treatment options for patients with limited therapeutic alternatives.